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Background: The number of elderly people over the age of 65 commencing dialysis in NZ has increased by almost
400% in the past decade. Few data are available about health related outcomes and survival on dialysis in the
elderly to help the individual, their family, clinicians and health planners with decision-making.
Methods/design: This study will provide the first comprehensive longitudinal survey of health-related quality of life
(HRQOL) and other patient centred outcomes for individuals aged ≥65 years on, or eligible for, dialysis therapy and
will link these data to survival outcomes. Data collected by yearly structured interviews with participants will be
linked to co-morbidity data, health service use, and laboratory information collected from health records, and
analysed with respect to HRQOL and survival. The information obtained will inform the delivery of dialysis services
in New Zealand and facilitate improved decision-making by individuals, their family and clinicians, about the
appropriateness and impact of dialysis therapy on subsequent health and survival.
Discussion: Results from this study will make possible more informed decision-making by future elderly patients
and their families as they contemplate renal replacement therapy. Results will also allow health professionals to
more accurately describe the impact of dialysis therapy on quality of life and outcomes for patients.
Trial registration: ACTRN12611000024943.
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There has been an increase of over 400% in the number
of elderly and very elderly patients on dialysis in New
Zealand over the past 2 decades [1]. This rapid increase
has generated considerable debate resulting in wide vari-
ation in attitude towards referral and acceptance of eld-
erly patients for dialysis [2-5]. One major reason for this
is that there is uncertainty about the outcome from dia-
lysis treatment in this population. Decision-making
should, and clearly does, involve the patients and their
carers’, along with health service providers. However,
there is currently a dearth of evidence related to such
decision-making among dialysis patients in general, and
elderly dialysis patients in particular [6].
The assumption is often made that dialysis is appro-
priate for all individuals; however this may not be a
valid assumption. Dialysis by the nature of the interven-
tion has a large potential to negatively influence the* Correspondence: Rob.walker@otago.ac.nz
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reproduction in any medium, provided the orquality of life of the individual and immediate family.
While dialysis usually prolongs life in people with end
stage kidney disease (ESKD), it has also been found that
both patients and their partners are overwhelmed by
the impact of dialysis on their lives [4]. Dialysis may
substantially worsen quality of life especially in those
with significant co-morbidity. However, if patients opt
for conservative therapy (no dialysis) it is unknown how
much life expectancy and quality of life is actually al-
tered. There are currently few scientific data to inform
and help clinicians, their patients and family to make a
decision.
In addition to the impact of dialysis treatment on the
individual, there is a significant health-economic impli-
cation for NZ, with the approximate cost of dialysis per
individual at about $65,000 to $80,000 per year. In New
Zealand, this equates to approximately $56 million per
year for those on dialysis over the age of 65 years. This
cost does not include the cost of hospitalisation and the
impact of any other associated co-morbidity that is fre-
quently present in the elderly and may be exacerbatedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for renal replacement therapy (RRT) can currently be
estimated, there is no information about patient-
experienced benefits to the individuals beyond survival.
The determinants of successful dialysis in the elderly
will be multifactorial including the degree of autonomy
or control related to managing dialysis (home care ver-
sus satellite or in-centre based care), and the many
socio-economic factors related to the management of a
chronic disease superimposed upon the aging process.
A recent study from a large London dialysis centre
looked at outcomes between two groups of older pa-
tients, one group that opted for dialysis therapy and the
other that chose maximal conservative care [6]. Those
opting for conservative care were older (mean age
82 years versus 76 years). Although the dialysis group
survived for a longer period (mean 2 years), the majority
in the conservative group survived for over 13 months
with substantially lower hospital days (16 days/per pa-
tient/year) and the majority in this group died at home
[6]. The dialysis patients were dialysed in a hospital
centre, that meant these patients averaged 173 days/per
patient/year at the hospital. This study did not record
any QoL assessment, data related to patient satisfaction,
cost-effectiveness or the socio-economic impact of the
hospital-based treatment [6].
In a thematic analysis of the literature Morton and
colleagues demonstrated that awareness of factors asso-
ciated with decision-making related to the management
of CKD can provide health professionals with evidence
on how best to deliver education programmes for pa-
tients and their family, as well as enhancing the patient
and their family’s capacity to share in that decision mak-
ing process [7]. They identified 4 themes – confronting
mortality (life/death, burden on family, state of limbo),
lack of choice (options not always discussed), know-
ledge of options, and weighing the alternatives [7].
These are the important issues that this study will focus
upon.
It is vital for future health care delivery of renal re-
placement therapy in those aged ≥65 years in New
Zealand that reliable data are obtained. It is also import-
ant to have accurate data upon which to base priority
decisions regarding health funding and outcomes. In
2008, there were 154 new patients over 65 years com-
mencing dialysis. This is a rate of 397 per million for
elderly patients, compared to the overall rate of new pa-
tients for New Zealand at 109 per million [1].
Aims
1) To determine the impact of age, sex, ethnicity,
duration of dialysis, satisfaction with health services
and co-morbidity on the health-related quality of life(HRQoL) in elderly patients (≥65 years) with
chronic and end-stage kidney disease (CKD, ESKD).
2) Compare and contrast survival, health service
utilisation, costs and HRQoL outcomes of older
patients with EKSD according to the type of renal
replacement therapy including modality
(haemodialysis versus peritoneal dialysis) and
location (home versus facility) or maximal
conservative therapy (no dialysis).
3) To develop evidence-based guidelines for optimal
management of older patients with severe CKD and
ESKD.
Hypotheses
From the cross-sectional data at baseline, we hypothesise
that HRQoL differs between patients according to: sex,
ethnicity, co-morbidities, type of dialysis treatment,
health service satisfaction, costs, family support and dur-
ation of dialysis.
From longitudinal data in Years 2 and 3, we hypothe-
sise that: HRQoL is positively associated with survival
and that the HRQoL trajectory will differ between pa-
tients of different sex, ethnicity, co-morbidities, type of
dialysis, availability of family and community support
and duration of dialysis.
Methods/Design
Study design
The study uses an “accelerated longitudinal design”,
comprised of cross-sectional and longitudinal compo-
nents. The cross-sectional data are collected at the
baseline interview and from clinical records in Year 1.
The longitudinal data are collected from interviews 2
and 3 (12 and 24-months after the initial interview) and
from clinical records in Years 2 and 3. This study design
is optimal since it: 1) allows for the provision of timely
results from an initial cross sectional analysis, and 2) by
including the prevalent dialysis patients at baseline and
the incident patients eligible for dialysis each year, it
also allows for sufficiently powered longitudinal ana-
lyses, without the need for extended recruitment that
would be necessary if the study used a dialysis inception
cohort.
The nephrology teams responsible for their medical
care have undertaken the identification of potential par-
ticipants. All eligible (and consenting) participants will
be contacted by telephone to arrange an interview. Data
will be collected at each of the three interviews using
structured questionnaires administered to participants
by trained interviewers and from clinical records by the
research nurses. The first Baseline Interview will be ad-
ministered to all eligible participants already on dialysis
for at least 90 days at the start of the study and to all
new patients who are eligible for dialysis each year.
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vors 12 and 24-months later. The questionnaires have
been piloted with 60 older patients with CKD and found
to be acceptable and to cover questions and issues of
greatest relevance to them [8]. Each interview will be
designed to take 45-60 minutes and will be conducted
either on the telephone or face to face depending on pa-
tient preference.
Study participants
Our cohort will consist of dialysis and pre-dialysis patients
recruited from three services across New Zealand, each
serving different patient populations using contrasting
models of care for dialysis delivery. These are: Middlemore
Hospital (Counties Manukau District Health Board (DHB)),
the largest dialysis service in New Zealand, providing both
home and facility-based dialysis in mostly urban settings in-
cluding a large proportion of New Zealand Māori and
Pacific population; Dunedin Hospital (Southern DHB), a
medium sized dialysis service providing entirely home-
based dialysis in mixed urban and rural settings; and Hast-
ings Hospital (Hawkes Bay DHB), a small sized dialysis ser-
vice providing both home and facility-based dialysis in
mostly rural settings. There is always a tension between the
number of sites and speed of recruitment and the desire to
carefully manage recruitment and the study process. By
recruiting from three sites we ensure a range of participant
characteristics in the study that are representative of New
Zealand, while also ensuring that the study is efficient in
terms of project management and data analysis. Using
registry data from the Australian & New Zealand Dialysis
and Transplant registry (ANZDATA), and a recruitment
rate of 70%, it is estimated that we will enroll 160 to
172 prevelant participants and approximately 40 incident
participants in the first year (Figure 1).
All patients will be followed prospectively including
those who decide not to undertake dialysis, to exploreFigure 1 Presenting Recruitment and Follow-up (assuming an 70% rechanges in their HRQoL and survival status. The effects
of age, sex, ethnicity, co-morbidities, modality, duration
of dialysis treatment, family support and prior HRQoL
on current quality of life and survival will be examined.
Interview questionnaires include the SF-36 [9], the
Kidney Disease Questionnaire [10] (KDQoL) EQ-5D
[11,12]), WHODAS [13]. Inclusion of the KDQoL will
make possible the comparison of the SF-36 health
status of participants with other groups within New
Zealand and will also provide kidney disease-specific in-
formation for comparing outcomes with international
studies [14-17].
Inclusion criteria
1) Prevalent dialysis patients under the three dialysis
services aged ≥65 years who have been on dialysis
for 90 days prior to survey date will be eligible to
participate in the study.
2) Incident chronic kidney disease patients aged ≥65 years
with an eGFR ≤15 ml/min/1.73 m2 presenting to the
same services for consideration of dialysis will be
eligible to participate in the study. A proportion of
these patients will decide not to undertake dialysis.
They will provide important data to compare and
contrast with those who commence dialysis.
3) Patients aged ≥65 years who present with hitherto
unrecognized renal failure requiring immediate
dialysis will be eligible if their renal failure is deemed
permanent by the treating nephrologist, and if
dialysis is intended to be an indefinite treatment.
Exclusion criteria
1) Inability to give informed consent
2) Inability to participate in a telephone or face-to-face
interviewsponse rate).
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(current and within 2 weeks of the survey period)
and of sufficient severity to affect the patient’s
ability to take part in the opinion of the treating
physician (interviews for this last group will be
rescheduled for 1 month later). Note that any
selection bias introduced by this exclusion will be




Most questions within the structured questionnaire
are closed-response questions amenable to quantita-
tive analysis. Most of these questions were trialled in
a pilot study by us and found to be acceptable to pa-
tients [8]. The structured questionnaires also collect
some information in ‘free-text/open-ended response’
format about participants’ decision-making about
commencing dialysis, and dialysis type (haemodialysis
or peritoneal) and their experience and perceptions of
dialysis which will be analysed thematically. The inter-
views comprise
1. Kidney disease - The shorter version KDQol, [18-20]
which includes the SF-36 [9] and Kidney Disease
Questionnaire [10]. Inclusion of the KDQoL will
make possible the comparison of the SF-36 health
status of participants with other groups within New
Zealand and also will provide kidney disease-specific
information for comparing outcomes with
international studies [14-17]. The KDQoL also
includes a number of questions specifically enquiring
about: managing kidney disease, CKD symptoms,
effect of CKD on daily life and satisfaction with
dialysis care.
2. General Health Status - EQ-5D. It is applicable to a
wide range of health conditions and treatments; it
provides a simple descriptive profile and rating of
health status of use for within-study group
comparison, economic analyses and for international
comparison of health status outcomes [21]. New
Zealand population norms are available for the EQ-5D
(25) [22]. The alcohol use disorders identification test
(AUDIT) was used to assess alcohol consumption [23]
and some additional questions on illicit drug use using
the AUDIT were added.
3. Disability - The WHODAS II, a short 12-question
of measure of disability is one of few measures
specifically designed to measure disability according
to the World Health Organisation ICF model of
disability [24]. Subjective wellbeing was measured
using the Australian instrument, the Personal
Well-Being Index [25].4. Social Supports: 1) Residential status, including
residential care and extended family support;
2) ability to perform independent dialysis treatment
and/or any assistance required from family or
friends; 3) what, if any, help is required by the
patient around the home.
5. Economic Burden and Personal Costs: Three
questions, modelled on the Ministry of Social
Development sponsored study into the Living
Standards of Older People [26] to discover financial
burden for comparison with data from the general
population. Information will also be collected about
personal costs incurred as a result of dialysis [8].
6. Mental health: Depressive symptoms are common
in chronic disease and have been shown to be
related to survival in some studies [27] but not in
others [28]. The relationship between depression
and survival in the elderly dialysis population
remains to be defined and there may be a positive
relationship between age and emotional state [29].
We are measuring this with questions from the SF-
36 scale and a question from the EQ-5D [9].
7. Demographic data: Data about ethnicity, descent
from New Zealand Māori, household composition
and home ownership will be collected as per the
New Zealand Census [30].
Clinical records
1. Co-morbidity:Following participants consent,
research staff will collect these data from
participants’ clinical records. Co-morbidity may have
significant influence on outcome with adverse effects
on survival depending on specific conditions like
diabetes, ischaemic heart disease and peripheral
vascular disease [14]. Several indices of co-morbidity
have been used for patients with chronic kidney
disease and dialysis populations, for example: the
Khan [31], Davies [32], and the Charlson [33]
indices. However these were derived for general
populations, not specifically CKD populations. We
plan to utilise a newer improved co-morbidity index,
validated against the USRDS end stage renal failure
population, that is simpler, easier to use and has
been shown to outperform the Charlson co-
morbidity index [34]. It applies numerical weights to
co-morbid conditions including atherosclerotic heart
disease, congestive heart failure, cardiovascular
disease, peripheral vascular disease, dysrhythmias,
chronic airways disease, liver disease, cancer and
diabetes. The sum of the weights present for the
individual can be used as a continuous variable in
analyses [34]. This will be linked to health service
utilisation and adverse outcomes.
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and health service utilisation: Data about survival,
adverse outcomes, laboratory data and health service
utilisation (including hospital admissions and length
of stay) will also be collected from clinical records.
Trial registration
Australian and New Zealand clinical trials registry:
ACTRN12611000024943.
Ethical approval
The study protocol was approved by the New Zealand
Multi-Regional Ethics Committee, approval number
MEC/10/084.
Data analysis
All analyses will be performed using Stata 11.0 (or sub-
sequent versions). Confidence intervals will be provided
in all cases. All data will be described using appropriate
summary statistics and frequency tables where necessary.
Associations between the variables will be assessed in
terms of statistical significance at a level of P <0.05.
Cross sectional analysis from baseline data
Linear mixed models will be used to model quality of life
measures (accounting for clustering within centres)
based on subject demographics (including age, sex, eth-
nicity, socioeconomic status), co-morbidities, and mo-
dality and duration of dialysis. The prevalent dialysis
participants will be grouped for analysis according to
their vintage on dialysis, and combined for analysis with
the incident patients in Year 1. Differences between cat-
egorical measures (e.g., ethnicity) will be assessed using
adjusted means. Relationships between continuous mea-
sures (e.g., quality of life and dialysis duration) will be
assessed using correlations. The study is powered at 80%
to detect differences between means of 0.55 standard de-
viations for two groups sized 106 patients each (half of
the sample), and differences of 0.8 standard deviations
between two groups sized 53 patients each (quarter of
the sample). These detectable differences are considered
to be of clinical importance.
Longitudinal analysis
Mixed models will be used for the majority of the longi-
tudinal analyses to estimate the trajectory of HRQoL
over time. Correlation between repeated measures
within centres and participant will be accounted for. Dif-
ferences between groups at different time points will be
assessed using adjusted means. Assuming a design effect
of 2 for the quality of life instruments in the target
population and a correlation of 0.65 between a partici-
pant’s repeated measurements, the study would be
powered at 80% to detect changes as small as 0.45standard deviations per six-month period within a group
containing 38 patients.Survival analysis
With the high mortality rate, 24 months of follow up of
this cohort will have sufficient power to determine im-
pact on survival. It will identify which key HRQoL mea-
sures provide the best discrimination and calibration in
determining outcome, so that an abbreviated assessment
can potentially be incorporated into evidence-based
guidelines to clinical practice. The survival analysis will
be performed initially using Cox’s proportional hazards
regression which has the potential to detect a hazard ra-
tio of 0.8 with 80% power, and p <0.05 will be considered
significant.Discussion
This project will clearly address the relevance, timeli-
ness, and the sustainability of dialysis in the older age
group. The provision of dialysis, preferably in a home
setting or low level self-care satellite units closer to the
individuals’ residences, may allow better integration with
primary and community care. If conservative manage-
ment is shown to be an important and valid option with
similar outcomes to dialysis, then this can be appropri-
ately discussed with the individual and their family with-
out this being considered as rationing, or limiting health
resources, to this age group (which is often a percep-
tion). Elderly patients who do not commence dialysis
often survive many months (6), and some may have a
better quality of life (HRQoL).
Providing information as to preferred options by this
age group related to their expectations and perceived
quality of life will immediately influence delivery of
healthcare. The data generated by this study will critic-
ally inform health care for the older age group.
Results from this study will make possible more in-
formed decision making by future elderly patients and
their families as they contemplate renal replacement
therapy. Results will also allow health professionals to
more accurately describe the impact of dialysis therapy
on quality of life and outcomes for patients.
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